Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing CG motifs
View Patent ↗Immunogenic compositions (e.g. vaccines) comprising: (a) an immunostimulating amount of a Neisseria antigen (preferably N. meningitidis serogroup B); and (b) an immunostimulating amount of an adjuvant composition comprising an oligonucleotide comprising at least one CG motif. Component (b) may further comprise a second adjuvant. Component (a) may be selected from a variety of antigens. Adjuvant compositions comprising an oligonucleotide having at least one CG motif, and complete Freund's adjuvant (CFA) are also provided.
1. An immunogenic composition comprising:
(a) an immunostimulating amount of a Neisseria antigen; and
(b) an immunostimulating amount of an adjuvant composition comprising:
(i) an oligonucleotide comprising at least one CG motif; and
(ii) an emulsion comprising submicron oil droplets and an emulsifying agent,
wherein the ratio of the emulsifying agent to the oil in said emulsion allows production of an emulsion wherein at least 80% of said oil droplets are less than 1 micron in diameter and wherein the oligonucleotide is at least 6 nucleotides and less than 100 nucleotides in length and comprises at least one phosphorothioate bond and the CG motif comprises an unmethylated CpG dinucleotide.
2. The composition of claim 1 , wherein said Neisseria antigen is selected from the group consisting of a protein, protein-polysaccharide, protein-lipopolysaccharide, polysaccharide, and lipopolysaccharide.
3. The composition of claim 1 or claim 2 , wherein said Neisseria antigen is from Neisseria meningitidis or Neisseria gonorrhoeae.
4. The composition of claim 3 wherein said Neisseria antigen is a Neisseria meningitidis serogroup B peptide.
5. The composition of claim 1 , wherein component (b) further comprises a second adjuvant.
6. The composition of claim 1 , wherein said emulsion comprises a metabolizable oil.
7. The composition of claim 6 , wherein said emulsion exists in the absence of any polyoxypropylene-polyoxyethylene block copolymer.
8. The composition of claim 7 , wherein said oil is an animal oil, an unsaturated hydrocarbon, a vegetable oil, or a terpenoid.
9. The composition of claim 8 wherein said terpenoid is squalene.
10. The composition of claim 9 , wherein said composition comprises 0.5 to 20% by volume of said oil in an aqueous medium.
11. The composition of claim 9 , wherein said emulsifying agent comprises a non-ionic detergent or a polyoxyethylene sorbitan mono-, di-, or triester or a sorbitan mono-, di-, or triether.
12. The composition of claim 9 , wherein said composition comprises 0.01 to 0.5% by weight of said emulsifying agent.
13. The composition claim 1 , further comprising a separate immunostimulating agent.
14. The composition of claim 13 wherein said immunostimulating agent is selected from the group consisting of a bacterial cell wall component and muramyl peptide.
15. The composition of claim 5 , wherein said second adjuvant comprises alum, incomplete Freund's adjuvant (IFA), or complete Freund's adjuvant (CFA).
16. The composition of claim 1 , wherein said oligonucleotide comprises at least one phosphorothioate bond.
17. The composition of claim 1 , wherein said oligonucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27.
18. The composition of claim 1 , wherein said oligonucleotide comprises a CG motif flanked by two purines immediately 5′ to said motif and two pyrimidines immediately 3′ to said motif.
19. The composition of claim 18 , wherein said oligonucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25.
20. A vaccine composition comprising:
a) an immunostimulating amount of a Neisseria meningitidis serogroup B antigen; and
b) an immunostimulating amount of an adjuvant composition comprising:
(i) an oligonucleotide comprising at least one CG motif; and
(ii) an emulsion comprising submicron oil droplets and an emulsifying agent, wherein the ratio of the emulsifying agent to the oil in said emulsion allows production of an emulsion wherein at least 80% of said oil droplets are less than 1 micron in diameter and wherein the oligonucleotide is at least 6 nucleotides and less than 100 nucleotides in length and comprises at least one phosphorothioate bond and the CG motif comprises an unmethylated CpG dinucleotide.
21. The vaccine composition of claim 20 , wherein component (b) further comprises a second adjuvant.
22. A method of stimulating an immune response in a host animal comprising administering to said animal a composition of claim 1 in an amount effective to induce an immune response.
23. The method of claim 22 wherein said host animal is a mammal.
24. A method of immunizing a host animal against Neisseria infection comprising administering to said animal a composition of claim 20 in an amount effective to induce a protective response.
25. The method of claim 24 wherein said host animal is a mammal.
26. The method of claim 25 wherein said mammal is a human.
27. A method of immunizing a host animal against Neisseria meningitidis comprising administering to said animal a composition of claim 20 in an amount effective to induce a protective response, wherein said antigen is a Neisseria meningitidis group B peptide.
28. The method of claim 27 wherein said peptide comprises SEQ ID NO: 31.
29. The method of claim 28 wherein said host animal is a human.
30. The composition of claim 10 , wherein the emulsifying agent comprises a non-ionic detergent or a polyoxyethylene sorbitan mono-, di-, or triester or a sorbitan mono-, di-, or triether.
31. The composition of claim 10 , wherein said composition comprises 0.01 to 0.5% by weight of said emulsifying agent.
32. The composition of claim 11 , wherein said composition comprises 0.01 to 0.5% by weight of said emulsifying agent.
33. An immunogenic composition comprising:
(a) an immunostimulating amount of a Neisseria meningitidis serogroup B antigen comprising SEQ ID NO: 31; and
(b) an immunostimulating amount of an adjuvant composition comprising:
(i) an oligonucleotide comprising at least one CG motif; and
(ii) an emulsion comprising submicron oil droplets and an emulsifying agent, wherein the ratio of the emulsifying agent to the oil in said emulsion allows production of an emulsion wherein at least 80% of said oil droplets are less than 1 micron in diameter and wherein the oligonucleotide wherein the oligonucleotide is at least 6 nucleotides and less than 100 nucleotides in length and comprises at least one phosphorothioate bond and the CG motif comprises an unmethylated CpG dinucleotide.
34. A vaccine composition comprising:
a) an immunostimulating amount of a Neisseria meningitidis serogroup B antigen comprising SEQ ID NO: 31; and
b) an immunostimulating amount of an adjuvant composition comprising:
(i) an oligonucleotide comprising at least one CG motif; and
(ii) an emulsion comprising submicron oil droplets and an emulsifying agent, wherein the ratio of the emulsifying agent to the oil in said emulsion allows production of an emulsion wherein at least 80% of said oil droplets are less than 1 micron in diameter and wherein the oligonucleotide is at least 6 nucleotides and less than 100 nucleotides in length and comprises at least one phosphorothioate bond and the CG motif comprises an unmethylated CpG dinucleotide.
35. A vaccine composition of claim 34 , wherein component (b) further comprises a second adjuvant.